세계의 전기생리학 시장 : 제품별, 적응증별, 최종사용자별, 지역별 - 예측(-2030년)

The global electrophysiology market is expected to reach USD 21.72 billion by 2030 from USD 12.55 billion in 2025, at a CAGR of 11.6% during the forecast period. The projected growth in the electrophysiology market is driven by technological advancements and increased research funding.

The worldwide shift toward value-based care and early intervention also encourages wider adoption of diagnostic EP tools like implantable loop recorders and wearable ECG devices. Additionally, the growth of telehealth after COVID-19 has improved access to remote arrhythmia monitoring and follow-up care. Increased government investment in cardiac programs, rising investments from public-private partnerships, and ongoing integration of AI and robotic navigation systems further improve procedure efficiency and standardization. Overall, these factors are fueling strong global expansion of the electrophysiology market.

"On the basis of product, the electrophysiology ablation catheters commanded the largest share in the electrophysiology market in 2024."

The electrophysiology market is categorized into several segments: electrophysiology laboratory devices, electrophysiology ablation catheters, electrophysiology diagnostic catheters, EP access products, and additional device types. The expansion of the electrophysiology (EP) ablation catheter sector is propelled by multiple factors. Notably, there is an increasing global incidence of atrial fibrillation (AF) and other cardiac arrhythmias, particularly within aging demographics, which heightens the demand for effective therapeutic interventions. Additionally, innovations in catheter technologies-such as contact force sensing, irrigated-tip designs, and pulsed field ablation-are enhancing safety, accuracy, and efficacy, thereby facilitating increased adoption among electrophysiologists.

"On the basis of indication, the atrial fibrillation devices segment held the largest share in the electrophysiology market in 2024."

By product, the electrophysiology market is segmented into atrial fibrillation, atrial flutter, atrioventricular nodal reentry tachycardia (AVNRT), wolff-parkinson-white (WPW) syndrome, and other indications. The expansion of the atrial fibrillation (AF) segment within the electrophysiology (EP) market is largely attributed to a convergence of demographic, lifestyle, clinical, and technological influences. The increasing global demographic of aging individuals, alongside rising rates of obesity, hypertension, diabetes, and sedentary behaviors, has led to a notable surge in AF prevalence. This growing burden of AF is driving heightened demand for EP diagnostics and therapeutic interventions. Moreover, significant advancements in EP procedural techniques, such as enhanced catheter ablation methods, state-of-the-art mapping systems, and sophisticated intracardiac imaging technologies, have markedly improved both the efficacy and safety profiles of interventions. These innovations are prompting clinicians to adopt ablation procedures earlier in the treatment continuum and with greater frequency, reflecting a paradigm shift in the management of AF.

"By region, North America accounted for the largest market share in 2024."

The electrophysiology sector in North America is experiencing robust expansion, primarily driven by the rising incidence of cardiac arrhythmias, notably atrial fibrillation. This trend correlates with an aging demographic and a high prevalence of comorbidities such as obesity, diabetes, and hypertension. Consequently, there is an escalating demand for advanced diagnostic and therapeutic electrophysiological procedures. Recent innovations-including 3D electro-anatomical mapping, enhanced radiofrequency and cryoablation technologies, and the introduction of pulsed-field ablation-have markedly improved procedural accuracy, patient safety, and clinical outcomes. These advancements are facilitating greater integration of electrophysiology practices within standard cardiology workflows.

"Asia Pacific to register the highest CAGR during the forecast period."

During the forecast period, the Asia Pacific (APAC) region is poised to experience considerable growth in the electrophysiology market. This region encompasses key markets such as India, China, Japan, Australia, South Korea, and Rest of Asia Pacific. The APAC electrophysiology market is witnessing a notable acceleration due to several interrelated factors. The escalating healthcare costs in major APAC countries-including China, India, Japan, and South Korea-are driving healthcare providers to adopt advanced medical technologies at an expedited pace. Enhanced healthcare infrastructure is facilitating this transition, allowing for greater accessibility to sophisticated electrophysiological devices. Moreover, the rising prevalence of cardiovascular diseases, attributable to demographic shifts such as aging populations, urbanization, and changing lifestyles, underscores the urgent need for effective diagnosis and treatment methodologies. Electrophysiology procedures, significantly relied upon for assessing and managing cardiac disorders, are consequently fueling demand for associated diagnostic and therapeutic devices within the region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
• By Designation: C-level-27%, Director-level-18%, and Others-55%
• By Region: North America-50%, Europe-20%, Asia Pacific-15%, Latin America-10%, and the Middle East & Africa-5%

Key players in the electrophysiology market are Johnson & Johnson Services, Inc.(US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc.(US), MicroPort Scientific Corporation (China), BIOTRONIK (Germany), Teleflex Incorporated (US), Acutus Medical, Inc. (US), Merit Medical Systems (US), OSYPKA MEDICAL (Germany), Cook (US), Epmap-System (Germany), CathRx Ltd. (Australia), EP Solutions (Switzerland), CathVision (Denmark), TZ Medical, Inc. (US), APN Health, LLC (US), Lepu Medical Technology(Beijing)Co., Ltd (China), CardioFocus (US), Schwarzer Cardiotek (Germany), and Imricor (US).

Study Coverage:

The report analyzes the electrophysiology market and aims at estimating the market size and future growth potential of this market based on various segments such as devices & consumables, cancer type, procedure, end user, and region. The report also includes a competitive analysis of the key players in this market, along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall pressure monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers

• The report studies the electrophysiology market based on product, indication, end user, and region
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets concerning their growth trends, prospects, and contributions to the global electrophysiology market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Electrophysiology market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:

• Analysis of key drivers (technological innovations for advanced, effective, and easy-to-use electrophysiological devices; high geriatric population and increased prevalence of cardiovascular diseases; rising investments, funds, and grants for cardiac surgeries and electrophysiology; increasing cardiovascular disease incidence and procedural volume), restraints (high product cost and inadequate reimbursement in developing and under-resourced healthcare settings, unfavorable healthcare reforms in US); opportunities (substantial growth opportunities in emerging economies, popularity of ambulatory surgical centers offering cost-effective outpatient electrophysiology services), and challenges (global shortage of skilled and experienced personnel) influencing the growth of the electrophysiology market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the electrophysiology market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the Electrophysiology market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the electrophysiology market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), and Boston Scientific Corporation (US), among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Breakdown of primaries
    • 2.1.2.5 Key insights from primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS
  • 2.2.2 BOTTOM-UP APPROACH (SUPPLY-SIDE ANALYSIS)
  • 2.2.3 TOP-DOWN APPROACH (UTILIZATION RATE AND ADOPTION PATTERN)
  • 2.2.4 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS
• 2.3 GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH IMITATIONS
  • 2.6.1 SCOPE-RELATED LIMITATIONS
  • 2.6.2 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ELECTROPHYSIOLOGY MARKET OVERVIEW
• 4.2 NORTH AMERICA: ELECTROPHYSIOLOGY MARKET, BY PRODUCT AND COUNTRY
• 4.3 ELECTROPHYSIOLOGY MARKET: REGIONAL MIX
• 4.4 ELECTROPHYSIOLOGY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
• 4.5 ELECTROPHYSIOLOGY MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological innovations for advanced, effective, and easy-to-use electrophysiological devices
      • 5.2.1.1.1 Rising use of non-invasive cardiac mapping
      • 5.2.1.1.2 Increasing use of improved intracardiac ablation systems
      • 5.2.1.1.3 Rising use of MRI-guided ablation procedures
      • 5.2.1.1.4 Increasing ultrasound guidance in electrophysiology labs
    • 5.2.1.2 High geriatric population and increased prevalence of cardiovascular diseases
    • 5.2.1.3 Rising investments, funds, and grants for cardiac surgeries and electrophysiology
    • 5.2.1.4 Increasing cardiovascular disease incidence and procedural volume
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High product cost and inadequate reimbursement in developing and under-resourced healthcare settings
    • 5.2.2.2 Unfavorable healthcare reforms in US
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Substantial growth opportunities in emerging economies
    • 5.2.3.2 Popularity of ambulatory surgical centers offering cost-effective outpatient electrophysiology services
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Global shortage of skilled and experienced personnel
• 5.3 INDUSTRY TRENDS
  • 5.3.1 INTEGRATION OF DIGITAL TECHNOLOGIES, ARTIFICAL INTELLIGENCE, AND REMOTE MONITORING IN ELECTROPHYSIOLOGY
  • 5.3.2 ROBOTIC-ASSISTED ABLATION AND NAVIGATION TECHNOLOGIES FOR BETTER TRACTION IN ELECTROPHYSIOLOGY
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 3D mapping and navigation systems
    • 5.4.1.2 Cryoablation and radiofrequency ablation technologies
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Cardiac imaging technologies
    • 5.4.2.2 Robotic navigation systems
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 AI-enabled intravascular optical coherence tomography (OCT)
    • 5.4.3.2 AI-driven view guidance in intra-cardiac echocardiography (ICE)
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.5.2 BARGAINING POWER OF BUYERS
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 THREAT OF SUBSTITUTES
  • 5.5.5 THREAT OF NEW ENTRANTS
• 5.6 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.6.2 KEY BUYING CRITERIA
• 5.7 REGULATORY ANALYSIS
  • 5.7.1 REGULATORY FRAMEWORK
    • 5.7.1.1 North America
      • 5.7.1.1.1 US
      • 5.7.1.1.2 Canada
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
      • 5.7.1.3.1 Japan
      • 5.7.1.3.2 China
      • 5.7.1.3.3 India
    • 5.7.1.4 Latin America
      • 5.7.1.4.1 Brazil
    • 5.7.1.5 Middle East & Africa
      • 5.7.1.5.1 UAE
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 REIMBURSEMENT SCENARIO ANALYSIS
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT PUBLICATION TRENDS FOR ELECTROPHYSIOLOGY MARKET
  • 5.9.2 LIST OF KEY PATENTS
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA FOR HS CODE 901890, 2020-2024
  • 5.10.2 EXPORT DATA FOR HS CODE 901890, 2020-2024
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE SELLING PRICE TREND OF ELECTROPHYSIOLOGY PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.11.2 AVERAGE SELLING PRICE TREND OF ELECTROPHYSIOLOGY PRODUCTS, BY REGION, 2022-2024
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 UNMET NEEDS & END-USER EXPECTATIONS
• 5.14 VALUE CHAIN ANALYSIS
• 5.15 SUPPLY CHAIN ANALYSIS
• 5.16 ECOSYSTEM ANALYSIS
• 5.17 CASE STUDY ANALYSIS
  • 5.17.1 JOHNSON & JOHNSON TO EXPAND CARTO SUITE AND LEVERAGE AI FOR DECISION SUPPORT, VISUALIZATION, AND REMOTE DATA SHARING
  • 5.17.2 ABBOTT TO INTRODUCE ENSITE OMNIPOLAR TECHNOLOGY (OT) FOR ORIENTATION-INDEPENDENT MAPPING WITH PRECISE SIGNAL CLARITY
  • 5.17.3 PHILLIPS TO LAUNCH KODEX-EPD SYSTEM FOR ENABLING HIGH-RESOLUTION ANATOMICAL AND ELECTRICAL MAPPING WITHOUT DIRECT CATHETER CONTACT
• 5.18 ADJACENT MARKET ANALYSIS
• 5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.20 INVESTMENT & FUNDING SCENARIO
• 5.21 IMPACT OF AI/GEN AI ON ELECTROPHYSIOLOGY MARKET
• 5.22 IMPACT OF 2025 US TARIFF ON ELECTROPHYSIOLOGY MARKET
  • 5.22.1 KEY TARIFF RATES
  • 5.22.2 PRICE IMPACT ANALYSIS
  • 5.22.3 IMPACT ON COUNTRY/REGION
    • 5.22.3.1 North America
      • 5.22.3.1.1 US
    • 5.22.3.2 Europe
    • 5.22.3.3 Asia Pacific
  • 5.22.4 IMPACT ON END-USE INDUSTRIES
    • 5.22.4.1 Hospitals & clinics
    • 5.22.4.2 Ambulatory surgery centers

6 ELECTROPHYSIOLOGY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ELECTROPHYSIOLOGY LABORATORY DEVICES
  • 6.2.1 3D MAPPING SYSTEMS
    • 6.2.1.1 Development of alternative technologies to limit market growth
  • 6.2.2 ELECTROPHYSIOLOGY RECORDING SYSTEMS
    • 6.2.2.1 Increasing public-private funding for developing advanced novel recording systems to augment market growth
  • 6.2.3 RADIOFREQUENCY (RF) ABLATION SYSTEMS
    • 6.2.3.1 Cost-effectiveness and technological advancements to spur segment growth
  • 6.2.4 INTRACARDIAC ECHOCARDIOGRAPHY (ICE) ULTRASOUND IMAGING SYSTEMS
    • 6.2.4.1 Rising lifestyle- and age-related disorders to drive adoption for cardiac disease treatment
  • 6.2.5 ELECTROPHYSIOLOGY X-RAY SYSTEMS
    • 6.2.5.1 High incidence of cardiovascular disorders and availability of technologically advanced equipment to boost market growth
  • 6.2.6 REMOTE MAGNETIC & ROBOTIC NAVIGATION SYSTEMS
    • 6.2.6.1 Favorable reimbursement scenario to propel market growth
• 6.3 ELECTROPHYSIOLOGY ABLATION CATHETERS
  • 6.3.1 CRYOABLATION CATHETERS
    • 6.3.1.1 Therapeutic advantages and better clinical studies to drive market growth
  • 6.3.2 RADIOFREQUENCY (RF) ABLATION CATHETERS
    • 6.3.2.1 Technologically-advanced and safer catheters to drive adoption among healthcare professionals
  • 6.3.3 MICROWAVE ABLATION (MWA) CATHETERS
    • 6.3.3.1 Smaller diameter antennas, faster procedure times, and larger heating zones to aid market growth
  • 6.3.4 LASER ABLATION CATHETERS
    • 6.3.4.1 Launch of technologically-advanced laser ablation catheters to drive adoption in healthcare settings
• 6.4 ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
  • 6.4.1 CONVENTIONAL ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
    • 6.4.1.1 Development of technologically-advanced fixed and steerable diagnostic catheters to favor market growth
  • 6.4.2 ADVANCED ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
    • 6.4.2.1 Advanced electrophysiology diagnostic catheters to improve patient outcomes and optimize surgical procedures
  • 6.4.3 ULTRASOUND ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
    • 6.4.3.1 Availability of advanced ultrasound catheters and focus on supportive regulatory frameworks to drive segment
• 6.5 ELECTROPHYSIOLOGY ACCESS DEVICES
  • 6.5.1 LAUNCH OF ADVANCED ACCESS DEVICES TO ENHANCE EFFICIENCY DURING ABLATION CATHETER MAPPING AND POSITIONING
• 6.6 OTHER ELECTROPHYSIOLOGY PRODUCTS

7 ELECTROPHYSIOLOGY MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 ATRIAL FIBRILLATION
  • 7.2.1 DEVELOPMENT OF ADVANCED CARDIAC MAPPING SYSTEMS FOR EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
• 7.3 ATRIAL FLUTTER
  • 7.3.1 HIGH SUCCESS RATE OF RADIOFREQUENCY CATHETER ABLATION FOR TREATING ATRIAL FLUTTER TO PROPEL MARKET GROWTH
• 7.4 ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA (AVNRT)
  • 7.4.1 INCREASING EFFICACY OF ELECTROPHYSIOLOGY DEVICES FOR TREATMENT OF AVNRT TO AID MARKET GROWTH
• 7.5 WOLFF-PARKINSON-WHITE (WPW) SYNDROME
  • 7.5.1 PREFERENCE FOR RADIOFREQUENCY ABLATION OVER SURGERY TO AUGMENT MARKET GROWTH
• 7.6 OTHER INDICATIONS

8 ELECTROPHYSIOLOGY MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CARDIAC CENTERS
  • 8.2.1 PRESENCE OF BETTER CATHETERIZATION AND ELECTROPHYSIOLOGY LABORATORIES IN HOSPITALS TO SUPPORT MARKET GROWTH
• 8.3 AMBULATORY SURGERY CENTERS
  • 8.3.1 DEMAND FOR MINIMAL HOSPITAL STAYS AND HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET GROWTH
• 8.4 OTHER END USERS

9 ELECTROPHYSIOLOGY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American electrophysiology market during forecast period
  • 9.2.3 CANADA
    • 9.2.3.1 Growing government research funding to support market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Rising prevalence of atrial fibrillation and associated arrhythmias to propel market growth
  • 9.3.3 UK
    • 9.3.3.1 High geriatric population and rise in cardiac diseases to fuel market growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Favorable government healthcare policies and schemes to support market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Rising incidence of cardiovascular diseases to drive adoption of electrophysiology devices
  • 9.3.6 SPAIN
    • 9.3.6.1 Rising number of cardiac ablation procedures to drive adoption of electrophysoiology products
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 JAPAN
    • 9.4.2.1 Favorable reimbursement scenario and presence of universal healthcare policies to boost market growth
  • 9.4.3 CHINA
    • 9.4.3.1 Growing geriatric population and rising prevalence of cardiovascular diseases to favor market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Favorable government healthcare initiatives to support market growth
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing target disease burden and rising government funding to spur market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Supportive government initiatives to drive market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Modernization of healthcare facilities to propel market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Favorable investment scenario for medical device manufacturers to fuel market growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Kingdom of Saudi Arabia
      • 9.6.2.1.1 Rising number of private hospitals and increasing government financial support to fuel market growth
    • 9.6.2.2 UAE
      • 9.6.2.2.1 High clinical demand, increased government investment, and technological progress to aid market growth
    • 9.6.2.3 Rest of GCC Countries
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ELECTROPHYSIOLOGY MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Indication footprint
    • 10.5.5.5 End-user footprint
• 10.6 COMPANY EVALUATION MATRIX, STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of startups/SMEs
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 R&D ASSESSMENT OF KEY PLAYERS
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT LAUNCHES & APPROVALS
  • 10.10.2 DEALS
  • 10.10.3 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches and approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 ABBOTT
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 MEDTRONIC
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 KONINKLIJKE PHILIPS N.V.
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 GE HEALTHCARE
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product approvals and enhancements
      • 11.1.5.3.2 Deals
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 BOSTON SCIENTIFIC CORPORATION
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product approvals
      • 11.1.6.3.2 Deals
  • 11.1.7 JAPAN LIFELINE CO., LTD.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
  • 11.1.8 STEREOTAXIS, INC.
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 MICROPORT SCIENTIFIC CORPORATION
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product approvals
      • 11.1.9.3.2 Other developments
  • 11.1.10 BIOTRONIK
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Expansions
  • 11.1.11 TELEFLEX INCORPORATED
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
  • 11.1.12 ACUTUS MEDICAL, INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product approvals
  • 11.1.13 MERIT MEDICAL SYSTEMS
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Deals
  • 11.1.14 OSYPKA MEDICAL
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
  • 11.1.15 COOK
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 EPMAP-SYSTEM
  • 11.2.2 CATHRX LTD.
  • 11.2.3 EP SOLUTIONS
  • 11.2.4 CATHVISION
  • 11.2.5 TZ MEDICAL, INC.
  • 11.2.6 APN HEALTH, LLC
  • 11.2.7 LEPU MEDICAL TECHNOLOGY (BEIJING) CO.,LTD.
  • 11.2.8 CARDIOFOCUS
  • 11.2.9 SCHWARZER CARDIOTEK
  • 11.2.10 IMRICOR

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS